Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00915200
Other study ID # NIH 1R21AT004490
Secondary ID 1I01CX000264-01A
Status Completed
Phase Phase 2
First received June 2, 2009
Last updated June 23, 2016
Start date October 2009
Est. completion date April 2016

Study information

Verified date June 2016
Source The University of Texas Health Science Center at San Antonio
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The study is designed to test if the combination of two potent antioxidant nutritional supplements, N-acetylcysteine and the milk thistle extract silibin, is capable of correcting the shedding of urine protein, the oxidative stress, and the inflammation in patients with type 2 diabetes mellitus and diabetic kidney disease.


Description:

Oxidative stress and GSH imbalance are major contributors to the pathogenesis of diabetic nephropathy. Current options for the treatment of oxidative stress in diabetic nephropathy are limited and only partially effective, thus interest in the development of new strategies is high.

The study intends to test the hypothesis that combined oral supplementation of the antioxidants N-acetylcysteine (NAC) and milk thistle flavonolignan silibin (as silibin-phosphatidylcholine) will reduce proteinuria and urinary and systemic manifestations of oxidative stress and inflammation, which are characteristically observed in patients with type 2 diabetes mellitus and related nephropathy. We expect these effects to be achieved with minimal or no side effects, and with good patient tolerance.

The trial is designed as a two-center, double-blind, placebo-controlled, randomized, modified-factorial dose-ranging design, five-arm pilot study in patients with Type 2 diabetes mellitus and advanced diabetic nephropathy with proteinuria.

Intervention consists of three-month oral administration of NAC, silibin, and/or respective placebos for three months. Subjects are randomized to the following five intervention arms: (A) placebo; (B) NAC; (C) silibin; (D) NAC + silibin; and (E) NAC + double-dose silibin.

The primary outcome measure is urinary excretion of albumin, a marker of glomerular injury. Secondary outcome measures are alpha-1 microglobulin, a marker of tubular injury, and urinary excretion of inflammatory cytokines and C-C chemokines, i.e. markers of renal inflammation. In addition, peripheral blood monocytes from the same patients are analyzed for glutathione (GSH) content and activity of GSH metabolizing enzymes. All outcome measures are monitored in relation to both treatment allocation and prevalent blood and urine levels of the active treatment. Safety and tolerability of this combination treatment are monitored throughout the trial.


Recruitment information / eligibility

Status Completed
Enrollment 114
Est. completion date April 2016
Est. primary completion date April 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Males or females, age 18-70 years old.

- Type 2 diabetes mellitus

- Diabetic nephropathy, as defined by:

- estimated GFR between 60 and 15 ml/min,

- presence of proteinuria.

- Current medical treatment with low dose aspirin

- Treatment of hypertension with (but not limited to) one diuretic, one beta- blocker and one medication from the classes ARBs or ACE inhibitors.

- Treatment of hyperglycemia with (but not limited to) glipizide and the medication class insulin.

- Treatment of hypercholesterolemia with (but not limited to) one medication from the class statins.

Exclusion Criteria:

- Type 1 diabetes mellitus.

- Glycosylated hemoglobin (HbA1C) > 10%

- >20% variation in estimated GFR, during last 6 months

- SBP >170 mmHg or DBP >100 mmHg on medications

- Other secondary forms of hypertension (endocrine, renovascular)

- History of intolerance to:

- Both ACE-I and ARBs;

- The investigational supplements;

- Iodinated radiologic contrast material.

- Known non diabetic renal disease, or history of solid organ transplantation.

- Hepatitis virus or Human Immunodeficiency virus infections

- Use of one of the following medications within 2 months prior to enrollment in the study:

- Metformin.

- Thiazolidinediones (pioglitazone or rosiglitazone);

- Prescription-grade vitamin E, vitamin C, systemic steroids, and/or non-steroidal anti-inflammatory agents;

- Over-the-counter vitamin E, vitamin C, and/or non-steroidal anti-inflammatory agents.

- Over-the-counter antioxidants supplements including: Lipoic acid, Coenzyme Q10, N-acetyl-cysteine (NAC), Glutathione (GSH), Chromium, Fish-oil extracts (omega-3 fatty acids), Soy extracts (isoflavones), Milk thistle extract (silymarin), Green-tea preparations, Pomegranate extracts, Grape extracts, and Prickly pear extract.

- Active coronary artery disease or cerebral vascular disease within 3 months prior to signing the informed consent.

- Hepatic dysfunction as defined by abnormal total bilirubin or liver enzymes (ALT, AST) >2 times upper limit of normal range.

- Active malignancy.

- History of drug or alcohol dependency.

- Psychiatric or neurological condition, preventing aware consent to the study and/or adherence to the study protocol

- Unwillingness to practice birth control throughout the study.

- Participation to another clinical study within 1 month prior to signing the informed consent form.

- Planned move to outside the study area, surgery or radiographic studies utilizing iodine-based contrast material within the next one year

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Dietary Supplement:
N-acetylcysteine
600 mg orally twice daily for three months
silibin
480 mg orally twice daily for three months
high-dose silibin
960 mg orally twice daily for three months
N-acetylcysteine placebo
excipient orally twice daily for three months
silibin placebo
excipient orally twice daily for three months

Locations

Country Name City State
United States University of Texas Hlth Sci Ctr San Ant San Antonio Texas

Sponsors (3)

Lead Sponsor Collaborator
The University of Texas Health Science Center at San Antonio National Center for Complementary and Integrative Health (NCCIH), VA Office of Research and Development

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Urinary Albumin excretion 3-month No
Secondary urinary alpha-1 microglobulin excretion 3-month No
Secondary urinary C-C-chemokines excretion 3-month No
Secondary peripheral blood monocyte glutathione content 3-month No
Secondary tolerance and safety 3-month Yes
See also
  Status Clinical Trial Phase
Completed NCT03255187 - Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution N/A
Completed NCT04136821 - The Long-term Effects of Oceanix™ on Resistance Training Adaptations N/A
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Completed NCT03358524 - Effects of Vitamin E Supplementation on Free Radicals and Fat Level of Obese Adolescence in Jakarta, Indonesia Phase 4
Recruiting NCT05327348 - Effectiveness of IV Vitamin C in Reducing Oxidative Stress Associated With Free Flap Surgery Phase 3
Completed NCT03288623 - The Effects of Dark Chocolate Implementation in Elite Athletes N/A
Completed NCT04419025 - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease Phase 2
Completed NCT04597983 - Effect of 8-week Intake of 2S-hesperidin on Performance, Body Composition and Biochemicals Markers in Amateur Cyclists N/A
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A
Enrolling by invitation NCT03030456 - Whole Body Vibrations on Functional Capacity, Muscular Strength, and Biochemical Profile in Elders N/A
Not yet recruiting NCT02202239 - Effect of Induction and Maintenance of Anesthesia With Etomidate on Hemodynamics and Oxidative Stress in Diabetic Patients Phase 4
Completed NCT02256254 - SIMOX - Induction of Oxidative Stress Phase 2
Recruiting NCT02048592 - Impact of Immunonutrition on the Patients With Cystic Fibrosis Phase 4
Completed NCT01942460 - Ferumoxytol for Iron-Deficiency Anemia in Chronic Kidney Disease and Peritoneal Dialysis Patients Phase 4
Completed NCT02463318 - The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy Subjects N/A
Completed NCT02177383 - Action of Essential Fatty Acids on the Expression of Antioxidant Genes and Athletic Performance N/A
Completed NCT01990391 - Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities N/A
Completed NCT00845130 - Quantitative in Vivo Biomarkers of Oxidative Stress in Diabetes N/A
Completed NCT00607893 - Efficacy of Continuous Positive Airway Pressure in Reducing Oxidative Stress in Individuals With Sleep Apnea N/A
Active, not recruiting NCT00247507 - The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Phase 4